Loading...
Market
How will MariTide impact Amgen's revenue in fiscal year 2025?
2
Resolution / Starting Odds
Increases revenue by more than 5% • 25%
Increases revenue by up to 5% • 25%
No significant impact on revenue • 25%
Decreases revenue • 25%
Amgen's financial reports and earnings calls
Story
Amgen's MariTide Achieves 20% Weight Loss in Phase 2; Shares Drop 12%
Nov 26, 2024, 12:20 PM
Amgen Inc. announced that its experimental obesity drug, MariTide (maridebart cafraglutide), a GLP-1/GIPR agonist, demonstrated up to 20% average weight loss at 52 weeks in a Phase 2 study involving people with obesity or overweight. In patients with Type 2 diabetes, the drug achieved approximately 17% weight loss and lowered HbA1c levels by 2.2 points. The study showed no weight-loss plateau and reported a gastrointestinal dropout rate of less than 8%. Amgen scheduled a conference call at 8 am ET to discuss the data. Despite the promising results, Amgen's stock price fell by up to 12% in premarket trading, indicating that the data may have fallen short of market expectations.
View original story
Similar markets
Exceeds forecasts • 25%
Meets forecasts • 25%
Below forecasts • 25%
Significantly below forecasts • 25%
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Revenue decrease due to MRT-6160 • 25%
Revenue increase due to MRT-6160 • 25%
No significant financial impact • 25%
MRT-6160 discontinued • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%